This involves assessing tumor aggressiveness and measuring several cancer markers, including carcinoembryonic antigen (CEA), hypoxia-inducible factor 1 α (HIF1α), tumor suppressor p53, as well as the metastatic marker matrix metalloprotein-9 (MMP-9) and vascular endothelial growth factor (VEGF). The gene discussed is CEACAM5; the disease is cancer.